CalciMedica, Inc.
NCM: CALCLive Quote
📈 ZcoreAI Score
Our AI model analyzes CalciMedica, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get CALC Z-Score →About CalciMedica, Inc.
Healthcare
Biotechnology
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
📊 Fundamental Analysis
CalciMedica, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -761.0%, which indicates that capital utilization is currently under pressure.
At a current price of $0.62, CALC currently trades near the bottom of its 52-week range (2%), indicating potential value or weakness (Range: $0.46 - $7.20).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$9.73M
Trailing P/E
--
Forward P/E
-0.38
Beta (5Y)
1.09
52W High
$7.20
52W Low
$0.46
Avg Volume
1.29M
Day High
Day Low